EMEA Liquid Biopsy Market Overview: 2023-28
Base Year: 2022
Historical Years: 2018-21
Forecast Years: 2023-28
TheEMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28. The market noticed consistent growth since the past few years, owing to the increasing prevalence of cancer patients coupled with a surge in demand for minimally invasive & fast diagnostic tests for detection. The rising prevalence of cancer has affected patients in the EMEA region, owing to the sedentary lifestyle, harmful carcinogenic elements in the environment, etc. According to the World Health Organisation (WHO), there were around 4 million cancer cases in Europe in 2020, of which nearly 2.4 million cases were in men & over 2.1 million in women.
Markntel Advisor’s EMEA Liquid Biopsy Market Insights report provides the current and forecast market analysis, individual leading companies’ market shares, challenges, EMEA Liquid Biopsy Market drivers, barriers, EMEA Liquid Biopsy Market Trends, and Key Players in EMEA Liquid Biopsy Market.
Download a sample copy of the Report: https://www.marknteladvisors.com/query/request-sample/emea-liquid-biopsy-market.html
✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.
EMEA Liquid Biopsy Market Dynamics: 2023-28
Prevalence in the Number of Cancer Patients Would Generate the Demand for Liquid Biopsy – Cancer has been a chronic disease over the past years & would continue to ascend in the forecasting year as well, owing to the increasingly sedentary lifestyle, smoking, and drinking habit of the individual, which would require better diagnostic facilities, treatment, and care for the patients. The continuous boost in the number of cancer patients emphasizes the need for accurate & convenient diagnostic systems for early cancer detection. Consequently, with the rising number of cancer patients, especially across Turkey, France, Denmark, etc., the usage of Liquid Biopsy is also uplifting. The advantages of liquid biopsy, like lower cost, early prognosis, therapy monitoring, etc., have further enhanced their adoption over conventional diagnostic methods to detect urothelial carcinoma, non-urological cancers, and other blood cancers.
The use of liquid biopsy has also been upscale to determine the best treatments for cancer patients, especially lung & prostate cancer, in which the patient receives specific targeted drugs. Hence, the improved investments by government organizations & pharmaceutical companies to escalate the research & development of new cancer treatments are anticipated to augment the growth of the EMEA Liquid Biopsy Market during the forecasted period.
Browse Full Report with Detail Analysis – https://www.marknteladvisors.com/research-library/emea-liquid-biopsy-market.html
EMEA Liquid Biopsy Market (2023-28): Segmentation Outlook
The market report has segmented the market into the following categories:
- By Product and Services
- Equipment
- Assay Kits
- Services
- By Circulating Biomarker
- Circulating Tumour Cell (CTC)
- Circulating Tumour DNA (ctDNA)
- Cell Free DNA (cfDNA)
- Extracellular Vesicle (EVS)
According to report, Circulating Tumour DNA (CTDNA) markers are anticipated to gain significant market share in forecasted years, as they provide opportunities for molecular diagnosis of cancer to analyze tumor progression & recurrence.
- By Technology
- Multi gene analysis by Next Generation Sequencing (NGS)
- Single gene analysis by Polymer chase reaction (PCR)
- By Sample Type
- Blood
- Urine
- Others (Cerebrospinal Fluid, Plasma, Saliva, etc.)
According to report, Blood Sample-based Testing dominated the EMEA Liquid Biopsy Market during the historical years, as it is highly preferred by cancer patients owing to its least invasive nature & reduced risk of incision into the body.
- By Application
- By Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma cancer
- Others (Pancreatic, Liver, etc.)
- By Non Cancer Application
- Non Invasive Parental Testing
- Organ Transplantation
- Infectious Diseases
- By Clinical Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
- By Cancer Application
- By End User
- Hospital and Physician laboratories
- Reference Laboratories
- Academic & Research Centre
- By Country
- Germany
- The UK
- France
- Italy
- Spain
- Saudi Arabia
- The UAE
- Egypt
- South Africa
- Rest of Europe Middle East & Africa
Note – If there are any particular details you need that are not currently included in the report, we will be happy to provide them as part of our customization services.
Top Companies Operating in the EMEA Liquid Biopsy Market:
- Thermofisher Scientific
- Hoffmann-La Roche Ltd
- Sysmex Corporation
- Qiagen N.V.
- Guardant Health
- Bio Rad
- Neo Genomics
- Epigenomics
- Menarini-Silicon Biosystems
- Agena Bioscience Inc.
- Silicon Biosystems
- Pathway Genomics Corporation
- Others (Myraid Genetics, Illumina Inc.,etc)
Reports Delivery Format – Market research studies from MarkNtel Advisors are offered in PDF, Excel, and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address
About Us –
We are a leading market research company, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
Contact Us –
Email: sales@marknteladvisors.com
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Address Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
